Shopping Cart
- Remove All
Your shopping cart is currently empty
BN201
🥰Excellent
Catalog No. T14693Cas No. 1361200-34-1
BN201 (OCS-05) is a drug with neuroprotective and myelin repair effects, which acts mainly by activating serum glucocorticoid kinase-2 (SGK2), which in turn activates the FOXO3 pathway to promote neuronal survival and myelin repair. It is mainly used for the treatment of inflammatory neurological diseases such as multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).BN201 is able to regulate multiple kinases in the insulin growth factor 1 (IGF1) pathway and cross the blood-brain barrier.
BN201
🥰Excellent
Purity: 99.73%
Catalog No. T14693Cas No. 1361200-34-1
BN201 (OCS-05) is a drug with neuroprotective and myelin repair effects, which acts mainly by activating serum glucocorticoid kinase-2 (SGK2), which in turn activates the FOXO3 pathway to promote neuronal survival and myelin repair. It is mainly used for the treatment of inflammatory neurological diseases such as multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).BN201 is able to regulate multiple kinases in the insulin growth factor 1 (IGF1) pathway and cross the blood-brain barrier.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $293 | In Stock | |
| 5 mg | $722 | In Stock | |
| 10 mg | $987 | In Stock | |
| 25 mg | $1,520 | In Stock | |
| 50 mg | $1,980 | In Stock | |
| 100 mg | $2,500 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BN201"
BRD7389
Cited
T14779376382-11-5
BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.
- $29
Size
QTY
CitedURMC-099
T60571229582-33-5
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
Aurora KinaseAutophagyBcr-AblCDKc-Met/HGFRDNA AlkylationIGF-1RLRRK2MEKMLKROCKSGKSrcSykTrk receptorVEGFR
- $52
Size
QTY
CKI-7
CKI-7 dihydrochloride, CKI7 dihydrochloride, CKI-7 2HCl, CKI7 2HCl, CKI 7 dihydrochloride, CKI 7 2HCl
T199131177141-67-1
CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
- $116
Size
QTY
GSK 650394
GSK650394
T2622890842-28-1
GSK 650394 is an inhibitor of serum- and glucocorticoid-regulated kinases (SGK) that inhibits SGK1 and SGK2 (IC50=62/103 nM). GSK 650394 has antitumor activity and also inhibits osteoclast differentiation and prevents bone loss.
- $34
Size
QTY
SI-113 Cited
T95891392816-46-4
SI-113 is a potent and selective inhibitor of SGK1, a serine/threonine protein kinase, that modulates several oncogenic signaling cascades.
- $38
Size
QTY
CitedPROTAC SGK3 degrader-1
SGK3-PROTAC1
T138472381320-35-8
PROTAC SGK3 degrader-1 (SGK3-PROTAC1) is a PROTAC coupler that targets SGK3 and binds ligand to VH032 VHL, inducing degradation of endogenous SGK3. It inhibits GDC0941-induced proliferation of cancer cells. [5017-88-83-4]
- $479
Size
QTY
PT109
T2012732059104-90-2
PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.
- Inquiry Price
Size
QTY
Ro-3306
Cited
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
- $32
Size
QTY
CitedSGK1-IN-4
T99771628048-93-0
SGK1-IN-4 is a selective inhibitor of SGK1 and can be used in studies about osteoarthritis.
- $113
Size
QTY
EMD638683 R-Form
T111811184940-47-3
EMD638683 is a highly selective SGK1 inhibitor with an IC50 of 3 μM. EMD638683 (R-Form) is the R-form of this compound.
- $193
Size
QTY
Select Batch
Purity:99.73%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | BN201 (OCS-05) is a drug with neuroprotective and myelin repair effects, which acts mainly by activating serum glucocorticoid kinase-2 (SGK2), which in turn activates the FOXO3 pathway to promote neuronal survival and myelin repair. It is mainly used for the treatment of inflammatory neurological diseases such as multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).BN201 is able to regulate multiple kinases in the insulin growth factor 1 (IGF1) pathway and cross the blood-brain barrier. |
| In vitro | BN201 promotes the survival of cultured neural cells when subjected to oxidative stress or when deprived of trophic factors[1]. BN201 (10 μM; 0.5-4 hours; Hela cells) treatment induces the phosphorylation of NDGR1 in Hela cells in a time-dependent manner[1]. |
| In vivo | 'Daily intraperitoneal injection of BN201 (12.5-150 mg/kg) for 30 days in female C57BL/6 mice results in reduced axonal and neuronal loss in the spinal cord and optic nerve compared to placebo-treated animals[1].' |
| Molecular Weight | 491.6 |
| Formula | C25H38FN5O4 |
| Cas No. | 1361200-34-1 |
| Smiles | O=C(N)CN(C(=O)CN(C(=O)CNCCC=1C=CC=CC1F)CC(C)C)CCCN2C(=O)CCC2 |
| Relative Density. | 1.192 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BN201 | purchase BN201 | BN201 cost | order BN201 | BN201 chemical structure | BN201 in vivo | BN201 in vitro | BN201 formula | BN201 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.